See Dr. Tibes' publications on PubMed

Selected Publications

  1. Tibes R, Trent J, Kurzrock R. Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics Annu Rev Pharmacol Toxicol. 2005; 45:357-84.
  2. Tibes R, Keating M, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning M, Faderl S. Activity of Alemtuzumab in CD52-Positive Acute Leukemias. Cancer. 2006 Jun 15; 106(12):2645-51
  3. Tibes R et al. Reverse Phase Protein Array (RPPA): Validation of a Novel Proteomic Technology and Utility for Analysis of Primary Leukemia Specimens and Hematopoetic Stem Cells (HSCT). Mol Cancer Ther. 2006 Oct; 5(10):2512-21.
  4. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced intensity conditioning regimens (RIC) for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007 Feb 15; 109(4):1395-400.
  5. Tibes R, Kornblau SM, Qiu Y, Mousses SP, Robbins C, Moses T, Carpten JD. PI3K/AKT Pathway Activation in Acute Myeloid Leukaemias is Not Associated With AKT1 Pleckstrin Homology (PH) Domain Mutation. Br J Haematol. 2008 Feb; 140(3):344-7
  6. *Kornblau SM, *Tibes R, et al. Functional Proteomic Profiling of Acute Myeloid Leukemias (AML) Predicts Response and Survival Outcome. Blood. 2009 Jan 1; 113(1):154-64. *Equal contribution
  7. Eisenman KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, Tibes R, Furge KA, Alberts AS. 5q- Myelodysplastic Syndromes: Chromosome 5q Genes Direct a Tumor Suppression Network Sensing Actin Dynamics. Oncogene. 2009 Oct 1; 28(39):3429-41.
  8. Von Hoff DD, LoRusso PM, Rudin CM, Reddy J, Yauch B, Tibes R, et al. Safety and Efficacy of GDC-0449 Hedgehog Pathway Inhibitor in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma in a Phase I Trial. N Engl J Med. 2009 Sep 17; 361(12):1164-72.
  9. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, Azorsa DO. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol. 2010 Sep; 118(3):220-7.
  10. Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, Sima C, Tibes R, Mousses S, Azorsa DO. RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma. Mol Cancer. 2010 Aug 18; 9(1):218. [Epub ahead of print]
  11. Amin SH, Tibes R, Von Hoff D, Kim J, Hybarger CP. Hedgehog Antagonist GDC-0449 Effective in the Treatment of Advanced Basal Cell Carcinoma. Larygoscope. (Epub)
  12. Shapiro G, Tibes R, Gordon M, et al. Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research.
  13. Tibes R, Piper B, Smith J, et al. Patient Willingness to Undergo Pharmacodynamic and Pharmacokinetic Tests in Early Phase Oncology Trials. Cancer.